Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

129
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
129
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

84
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
84
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

202
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
202
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

825
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
825
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

5.7K
Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
5.7K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

4.7K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug-Induced Hyperthermia Review.

Cureus·2022
Same author

Role of Clinical Pharmacists in Intensive Care Units.

Cureus·2021
Same author

Review of Medical Therapies for the Management of Pulmonary Embolism.

Medicina (Kaunas, Lithuania)·2021
Same author

Loperamide misuse and abuse.

Journal of the American Pharmacists Association : JAPhA·2017
Same author

Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease.

Current cardiology reviews·2016
Same author

Impact of Flipped Classroom Design on Student Performance and Perceptions in a Pharmacotherapy Course.

American journal of pharmaceutical education·2016

Related Experiment Video

Updated: Apr 25, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

22.2K

Is Community-Acquired Methicillin-Resistant Staphylococcus aureus Coverage Needed for Cellulitis?

Michael Horseman1, John D Bowman

  • 1Department of Pharmacy Practice, Rangel College of Pharmacy, Texas A&M Health Science Center, MSC 131, 1010 West Avenue B, Kingsville, TX, 78363-8202, USA.

Infectious Diseases and Therapy
|August 20, 2014
PubMed
Summary

Empirical methicillin-resistant Staphylococcus aureus (MRSA) coverage may not be necessary for non-purulent cellulitis. Beta-lactam therapy targeting streptococci appears sufficient for most community-acquired cellulitis cases.

More Related Videos

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

1.3K
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
14:04

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria

Published on: May 8, 2013

24.3K

Related Experiment Videos

Last Updated: Apr 25, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

22.2K
Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

1.3K
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
14:04

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria

Published on: May 8, 2013

24.3K

Area of Science:

  • Infectious Diseases
  • Antimicrobial Therapy
  • Dermatology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a prevalent pathogen in community-acquired skin and soft-tissue infections.
  • Empirical treatment strategies often include MRSA coverage for various infections.
  • The necessity of MRSA coverage for cellulitis remains a clinical question.

Purpose of the Study:

  • To evaluate the need for empirical methicillin-resistant Staphylococcus aureus (MRSA) coverage in the treatment of cellulitis.
  • To review the pathogenesis, microbiology, and current therapeutic studies for cellulitis.
  • To determine appropriate antimicrobial therapy for community-acquired cellulitis.

Main Methods:

  • Defined cellulitis and reviewed existing literature on its pathogenesis and microbiology.
  • Analyzed current inpatient and outpatient antimicrobial therapy studies.
  • Examined antibody studies to identify common etiologic agents.

Main Results:

  • Evidence suggests empirical MRSA coverage is not essential for non-purulent (non-suppurative) cellulitis.
  • Streptococci are identified as the most common etiologic agents in non-purulent cellulitis.
  • Most non-purulent cellulitis cases are not suitable for microbiological culture.

Conclusions:

  • Empirical MRSA coverage is likely unnecessary for non-purulent community-acquired cellulitis.
  • Beta-lactam therapy, targeting streptococci, is generally sufficient for non-purulent cellulitis.
  • Treatment decisions should consider the specific presentation and likely pathogens of cellulitis.